Bristol Myers Squibb Company (BMY) to Distribute Quarterly Dividend of $0.63 on November 2nd

Bristol Myers Squibb Company (NYSE:BMY) declared a quarterly dividend on Tuesday, September 15th. Shareholders of record on Friday, October 2nd will be given a dividend of 0.63 per share by the biopharmaceutical company on Monday, November 2nd. This represents a c) annualized dividend and a yield of 4.0%. The ex-dividend date is Friday, October 2nd.

Bristol Myers Squibb has increased its dividend by an average of 0.0%annually over the last three years and has raised its dividend annually for the last 17 consecutive years. Bristol Myers Squibb has a payout ratio of 41.5% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Bristol Myers Squibb to earn $6.44 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 39.1%.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $63.55 on Thursday. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $68.64. The stock has a fifty day moving average price of $63.99 and a 200-day moving average price of $60.12. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The firm has a market cap of $129.80 billion, a PE ratio of 14.00, a P/E/G ratio of 0.30 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company’s revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts predict that Bristol Myers Squibb will post 6.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BMY. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. UBS Group lowered shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 5th. Royal Bank Of Canada boosted their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research report on Friday, July 31st. Guggenheim reaffirmed a “buy” rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Finally, Wells Fargo & Company set a $65.00 price objective on Bristol Myers Squibb and gave the company an “equal weight” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $66.72.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.